在护士家访项目中加入亲密伴侣暴力干预对母亲生活质量的影响:一项随机临床试验
该整群单盲随机临床试验在美国8个州15个中心纳入492名社会经济弱势的孕妇,比较强化亲密伴侣暴力干预的护士家访项目与标准护士家访项目对母亲生活质量的影响。结果显示,两组生活质量从基线至产后24个月均有改善,但组间无统计学显著差异(模型化评分差值-4.9,95%CI -16.5至6.7),所有次要终点亦无显著差异。
要点
- 在护士家访项目中加入综合亲密伴侣暴力干预,并未显著改善产后24个月时的生活质量。
- 两组生活质量从基线至产后24个月均改善,但组间差异无统计学意义。
- 所有次要参与者终点均无统计学显著差异,两组均未记录不良事件。
核心结论
- 在准备初次为人父母的社会经济弱势孕妇中,与单独护士家访项目相比,加入综合亲密伴侣暴力干预并未显著改善产后24个月时的生活质量。
- 这些发现不支持使用该干预。
研究设计与样本
- 整群单盲随机临床试验,于2011年5月至2015年5月在美国8个州的15个中心开展。
- 纳入492名参与2.5年护士家访项目的社会经济弱势孕妇(≥16岁)。
- 强化项目组7个中心共229名参与者,标准项目组8个中心共263名参与者。
- 421名(86%)参与者完成试验,参与者平均年龄20.4岁。
主要发现
- 两组生活质量从基线至产后24个月均改善:强化项目组WHOQOL-BREF评分从299.5(SD 54.4)升至308.2(SD 52.6),标准项目组从293.6(SD 56.4)升至316.4(SD 57.5)。
- 基于多水平生长曲线分析,组间差异无统计学意义(模型化评分差值-4.9,95%CI -16.5至6.7)。
- 所有次要参与者终点均无统计学显著差异,两组均未记录不良事件。
临床怎么用
- 原文结论指出,这些发现不支持使用该干预。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Intimate partner violence (IPV) is a public health problem with significant adverse consequences for women and children. Past evaluations of a nurse home visitation program for pregnant women and first-time mothers experiencing social and economic disadvantage have not consistently shown reductions in IPV. OBJECTIVE: To determine the effect on maternal quality of life of a nurse home visitation program augmented by an IPV intervention, compared with the nurse home visitation program alone. DESIGN, SETTING, AND PARTICIPANTS: Cluster-based, single-blind, randomized clinical trial at 15 sites in 8 US states (May 2011-May 2015) enrolling 492 socially disadvantaged pregnant women (≥16 years) participating in a 2.5-year nurse home visitation program. INTERVENTIONS: In augmented program sites (n = 229 participants across 7 sites), nurses received intensive IPV education and delivered an IPV intervention that included a clinical pathway to guide assessment and tailor care focused on safety planning, violence awareness, self-efficacy, and referral to social supports. The standard program (n = 263 participants across 8 sites) included limited questions about violence exposure and information for abused women but no standardized IPV training for nurses. MAIN OUTCOMES AND MEASURES: The primary outcome was quality of life (WHOQOL-BREF; range, 0-400; higher score indicates better quality of life) obtained through interviews at baseline and every 6 months until 24 months after delivery. From 17 prespecified secondary outcomes, 7 secondary end points are reported, including scores on the Composite Abuse Scale, SPAN (Startle, Physiological Arousal, Anger, and Numbness), Prime-MD Patient Health Questionnaire, TWEAK (Tolerance/Worry About Drinking/Eye-Opener/Amnesia/C[K]ut Down on Drinking), Drug Abuse Severity Test, and the 12-Item Short-Form Health Survey (physical and mental health), version 2. RESULTS: Among 492 participants enrolled (mean age, 20.4 years), 421 (86%) completed the trial. Quality of life improved from baseline to 24 months in both groups (change in WHOQOL-BREF scores from 299.5 [SD, 54.4] to 308.2 [SD, 52.6] in the augmented program group vs from 293.6 [SD, 56.4] to 316.4 [SD, 57.5] in the standard program group). Based on multilevel growth curve analysis, there was no statistically significant difference between groups (modeled score difference, -4.9 [95% CI, -16.5 to 6.7]). There were no statistically significant differences between study groups in any of the secondary participant end points. There were no adverse events recorded in either group. CONCLUSIONS AND RELEVANCE: Among pregnant women experiencing social and economic disadvantage and preparing to parent for the first time, augmentation of a nurse home visitation program with a comprehensive IPV intervention, compared with the home visitation program alone, did not significantly improve quality of life at 24 months after delivery. These findings do not support the use of this intervention. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01372098.
引用
- Jack SM, Boyle M, McKee C, et al. Effect of Addition of an Intimate Partner Violence Intervention to a Nurse Home Visitation Program on Maternal Quality of Life: A Randomized Clinical Trial. JAMA. 2019. PMID: 31012933. doi:10.1001/jama.2019.3211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。